Hims & Hers Health (HIMS) Expands into Canada with a New Weight Loss Program

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the Stocks With Huge Catalysts on the Horizon. On July 9, Hims & Hers Health, Inc. (NYSE:HIMS) announced expanding into Canada with a new affordable weight loss program. The timing of this expansion has been matched with the first-ever availability of generic semaglutide, a popular weight loss medication.

Management noted that Canadians face high costs and lack access to proven weight loss treatments, whereas branded semaglutide costs more than C$200. The availability of generics is expected to lower prices and make treatment more accessible. Hims & Hers Health, Inc. (NYSE:HIMS) will offer these generic and low-cost options through its online platform, providing 24/7 access to licensed providers and personalized care plans.

Moreover, the company’s recent acquisition of European health platform ZAVA reflects its strategic plan to expand globally.

Hims & Hers Health, Inc. (NYSE:HIMS) is a digital health platform that connects consumers to licensed healthcare professionals for personalized care.

While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.